3/18
01:23 pm
inkt
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Medium
Report
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
3/18
07:48 am
inkt
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress [Yahoo! Finance]
Medium
Report
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress [Yahoo! Finance]
3/18
07:30 am
inkt
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
Medium
Report
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
3/4
07:30 am
inkt
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
Medium
Report
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
2/25
08:00 am
inkt
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target raised by analysts at HC Wainwright from $9.00 to $35.00. They now have a "buy" rating on the stock.
Medium
Report
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target raised by analysts at HC Wainwright from $9.00 to $35.00. They now have a "buy" rating on the stock.
2/24
09:04 am
inkt
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting [Yahoo! Finance]
Medium
Report
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting [Yahoo! Finance]
2/24
08:30 am
inkt
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
Low
Report
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
2/20
07:52 am
inkt
MiNK Therapeutics regains Nasdaq compliance [Seeking Alpha]
Low
Report
MiNK Therapeutics regains Nasdaq compliance [Seeking Alpha]
2/20
07:39 am
inkt
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements [Yahoo! Finance]
Low
Report
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements [Yahoo! Finance]
2/20
07:30 am
inkt
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
Low
Report
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
2/12
02:37 pm
inkt
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting [Yahoo! Finance]
Low
Report
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting [Yahoo! Finance]
2/12
01:00 pm
inkt
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
Low
Report
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
1/23
02:13 pm
inkt
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
Low
Report
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI